These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7145220)

  • 1. [The metabolism of calcium and phosphorus in diabetic nephropathies].
    Taboga C; Bertolissi F; Benedetti A
    Minerva Nefrol; 1982; 29(3 Suppl):29-35. PubMed ID: 7145220
    [No Abstract]   [Full Text] [Related]  

  • 2. Is anemia of chronic renal failure related to secondary hyperparathyroidism?
    Podjarny E; Rathaus M; Korzets Z; Blum M; Zevin D; Bernheim J
    Arch Intern Med; 1981 Mar; 141(4):453-5. PubMed ID: 7212887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of diabetes mellitus, age, and duration of dialysis on parathormone in chronic hemodialysis patients.
    Nasri H; Kheiri S
    Saudi J Kidney Dis Transpl; 2008 Jul; 19(4):608-13. PubMed ID: 18580021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate].
    Aresté N; Amor J; Cambil T; Salgueira M; Sánchez-Palencia R; Páez C; Gómez O; Palma A
    Nefrologia; 2003; 23 Suppl 2():64-8. PubMed ID: 12778857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total parathyroidectomy and autotransplantation.
    Diaz-Buxo JA; Geissinger WT; Walker PJ; Chandler JT; Farmer CD; Holt KL; Wolfe P
    Clin Nephrol; 1981 Dec; 16(6):276-82. PubMed ID: 7318261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attainment of the Japanese Society for Dialysis Therapy guidelines for the management of secondary hyperparathyroidism in chronic hemodialysis patients in our clinic.
    Sato Y; Eriguchi R; Umakoshi J; Kato M
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S48-53. PubMed ID: 17976086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperparathyroidism in CAPD patients: therapy with pulse oral calcitriol.
    Juergensen PH; Finkelstein FO; Cooper K; Santacroce S; Kliger AS
    Adv Perit Dial; 1993; 9():257-9. PubMed ID: 8105938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
    Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
    Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Phosphorus-calcium metabolism and the secretion of calcium-regulating hormones in diabetic nephropathy].
    Khasanova ER; Mkrtumian AM; Balabolkin MI
    Ter Arkh; 1994; 66(10):21-5. PubMed ID: 7863438
    [No Abstract]   [Full Text] [Related]  

  • 11. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A; Naderi AS
    Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
    Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe secondary hyperparathyroidism.
    Foerster D; Chmielewski C
    Nephrol Nurs J; 2001 Dec; 28(6):647-8. PubMed ID: 12143475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
    Block GA; Klassen PS; Lazarus JM; Ofsthun N; Lowrie EG; Chertow GM
    J Am Soc Nephrol; 2004 Aug; 15(8):2208-18. PubMed ID: 15284307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism.
    Kazama JJ
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S44-7. PubMed ID: 17976085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Parathormone and calcitonin in the blood in chronic kidney diseases].
    Mosin VM; Iagoda AV; Salanda BS; Derevianko NA
    Ter Arkh; 1982; 54(7):82-4. PubMed ID: 7135230
    [No Abstract]   [Full Text] [Related]  

  • 17. Microalbuminuria, another use for paricalcitol? Our experience in advanced chronic kidney disease.
    Blanco-García R; Bravo-López JJ; Moreiras-Plaza M; Nájera-de la Garza W; Cossio-Annibar C; Beato-Coo L; Rodríguez-Goyanes G
    Nefrologia; 2012 May; 32(3):401-2. PubMed ID: 22592429
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.
    Mehrotra R
    J Ren Nutr; 2006 Apr; 16(2):100-18. PubMed ID: 16567266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early assessment of secondary hyperparathyroidism.
    Peregrin T
    J Am Diet Assoc; 2006 Jan; 106(1):22-3. PubMed ID: 16390661
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.